PubMed Health⌕ Search

Biomedical subjects

Raxa Sankreacha

Publications and source records attributed to Raxa Sankreacha.

4 recordsLinked to original sources

Contamination during a brachytherapy procedure.

This paper describes an unusual contamination incident that occurred during the treatment of a prostate cancer patient with seeds containing 125I. The incident became particularly interesting as the radiation safety procedures in place prior to the incident were, in fact, inappropriate for the type of incident that occurred, resulting in a series of response errors. Strands containing 108 125I seeds with a total activity of 1.61 GBq (43.6 mCi) were implanted into a patient's prostate and the patient was sent to the recovery room. A radiation survey detected radiation levels of up to 15 microR h(-1), 10 cm from the surface of the implantation needles. Multiple individuals entered the room and were potentially exposed to contamination. Contamination was detected in a sample of the patient's urine, indicating that one or more implanted seeds were leaking. Initial test results for staff showed that 12 of 15 had thyroid levels potentially above their corresponding minimum detectable activity levels, with calculated thyroid burdens ranging from 0.17 kBq to 0.94 kBq, but, subsequent measurements, using each staff member's thigh counts as background, suggested that no staff member had been contaminated. The patient showed high uptake of 125I in his neck 10 d following the incident, estimated to correspond to an initial thyroid burden of 58 kBq. The possibility of contamination was not immediately considered due to the suspicion of the more common problem of a misplaced source. The initial measurements suggesting thyroidal contamination in staff point to an error in our thyroid screening method.

Brachytherapy↗

First report of a permanent breast 103Pd seed implant as adjuvant radiation treatment for early-stage breast cancer.

PURPOSE: A new technique of adjuvant partial breast irradiation using 103Pd permanent breast seed implants (PBSI) is presented. The procedure is performed in a single 1-hour session under local anesthesia. METHODS AND MATERIALS: Patients referred to a single institution for adjuvant radiotherapy after lumpectomy for an infiltrating ductal carcinoma < or = 3 cm in diameter, surgical margin > or = 2 mm, no extensive in situ carcinoma, no lymphovascular invasion, and minimal or negative lymph node involvement were offered a PBSI. RESULTS: Between May and December 2004, 31 eligible patients underwent CT scan and ultrasound simulations assessing PBSI feasibility. Fifteen were excluded because of feasibility issues, and 16 received PBSI. A minimal peripheral dose of 90 Gy was prescribed to the planning target volume corresponding to the clinical target volume identified on the CT scan plus a margin of 1 cm. The procedure was well tolerated; 56% of the patients reported no pain during the procedure, and 46% of the patients developed National Cancer Institute Common Toxicity Criteria Grade 1 acute reaction. None experienced toxicity Grade 2 or 3. CONCLUSIONS: Permanent breast seed implantation seems feasible and well tolerated on these preliminary clinical data and represents an ultimate step in the reduction of treatment fraction for partial breast irradiation.

Brachytherapy↗

A permanent breast seed implant as partial breast radiation therapy for early-stage patients: a comparison of palladium-103 and iodine-125 isotopes based on radiation safety considerations.

PURPOSE: A permanent breast seed implant (PBSI) technique has been developed as a new form of partial adjuvant radiation therapy for early-stage breast cancer. This study compares iodine-125 ((125)I) and palladium-103 ((103)Pd) isotopes by examining the exposure and effective dose (ED) to a patient's partner. METHODS AND MATERIALS: A low-energy survey meter was used to measure exposure rates as a function of bolus thickness placed over (103)Pd or (125)I seeds. A general mathematical expression for the initial exposure rate at 1 m (x(o,1m)) from the skin surface as a function of the implant size, R, and the distance between the skin surface and the implant, d, was derived. Also, a second general equation is proposed to calculate the ED to the patient's partner. RESULTS: The initial exposure rate at 1 meter and the ED are calculated as follows: x(o,1m) = 3alpha2R(3) ; ;beta(3) [e(-beta(2R+d))(betaR + 1) + e(-betad)(betaR - 1)], and ED = aR(b) [e(-c(2R+d)) (cR + 1) + e(-cd) (cR - 1)]. For (125)I, the parameters are: alpha = 0.154409, beta = 0.388460, a = 197, b = -0.95, and c = 0.38846. For (103)Pd, they are: alpha = 0.06877, beta = 0.421098, a = 18.6, b = -0.78, and c = 0.421098. For implant diameters varying from 2 to 6 cm and skin-to-implant distances varying from 0.7 to 4 cm, the ED is consistently below 2.6 mSv using the (103)Pd isotope, but more than 5 mSv in many instances and possibly up to 20 mSv using (125)I. CONCLUSIONS: PBSI using (103)Pd seeds appears safe because the patient's partner ED is consistently below 5 mSv. The(125)I isotope is not recommended for PBSI.

Algorithms↗

Comparative study of dosimetry between high-dose-rate and permanent prostate implant brachytherapies in patients with prostate adenocarcinoma.

PURPOSE: To compare the dose coverage, conformity, and homogeneity between high-dose-rate (HDR) brachytherapy and permanent prostate implant (PPI) in the treatment of prostate adenocarcinoma. METHODS AND MATERIALS: From January 2003 to August 2004, 54 patients (108 implants) underwent HDR brachytherapy of prostate cancer with iridium-192 stepping source. Of patients who underwent PPI brachytherapy with iodine-125, 72 patients were randomly selected for the purpose of dosimetric comparison. PPI preplan was done based on transrectal ultrasound study, and postplan was done using CT 1 month after implant. Dosimetric parameters of HDR were compared to that of PPI preplan and postplan. RESULTS: HDR brachytherapy had lower D90 (111.5% vs. 120.2%), lower V100 (97.2% vs. 99.6%), lower natural dose ratio (1.03 vs. 1.13), higher conformal index (0.69 vs. 0.62), and higher homogeneity index (0.63 vs. 0.52) than PPI preplan (all p < 0.0001). All the dosimetric parameters of PPI postplan including D90 (86.7%), V100 (82.0%), natural dose ratio (0.92), conformal index (0.53), and homogeneity index (0.42) were inferior to HDR brachytherapy (all p < 0.0001). CONCLUSIONS: HDR brachytherapy of the prostate can provide better dose coverage, conformity, and homogeneity compared to PPI.

Adenocarcinoma↗